// App-Quantinova.ai

P590 : Reasons for discontinuation and switch of biologic therapy in IBD: findings from a large international observational study (03)

Researchers

Presenter

  • S. Sebastian

Principal Investigators

  • B. Siegmund

  • D. Wolf

  • C.A. Siegel

  • G. Lichtenstein

  • E. Louis

  • X. Hebuterne

  • P.M. Ginsburg

  • A. Ostrov

  • M.Q. Ricci

  • M. Bernsen

  • I. Shafran

  • S. Nancey

  • G. Moran

  • N. Teich

  • S. Lal

  • M. Kiszka-Kanowitz

  • S. Murugesan

  • B. Moum

  • P. Dolin

Medical Centers

  • Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom

  • University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

  • Charite - University Medicine Berlin, Campus Benjamin Franklin, Deptartment of Neurology, Berlin, Germany

  • Atlanta Gastroenterology Associates, Atlanta, Georgia, United States

  • Dartmouth-Hitchcock Medical Center, Gastroenterology, Lebanon, United States

  • CHU Liege, Liege, Belgium

  • CHU de Lille, Department of Gastroenterology, Lille, France

  • Gastroenterology Centre of Connecticut, Hamden, Connecticut, United States

  • Saratoga Schenectady Gastro Associates, Burnt Hills, United States

  • Middlesex Gastroenterology Associates, Middletown, United States

  • Illinois Gastroenterology Group, Arlington Heights, United States

  • Shafran Gastroenterology Center, Winter Park, Florida, United States

  • CHU Rouen, Department of Gastroenterology, Rouen, France

  • Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, United Kingdom

  • Internistische Gemeinschaftspraxis, Department of Gastroenterology, Leipzig, Germany

  • Salford Royal Foundation Trust, Gastroenterology, Salford, United Kingdom

  • Herlev University Hospital, Department of gastroenterology, Herlev, Denmark

  • Blackpool Teaching Hospitals NHS Foundation Trust, Department of Gastroenterology, Blackpool, United Kingdom

  • Oslo University, Department of Gastroenterology, Oslo, Norway

  • Takeda Development Centre Europe, Pharmacoepidemiology, London, United Kingdom

Locations

  • United Kingdom

  • United States

  • Germany

  • Belgium

  • France

  • Denmark

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved